Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.
Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How
TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth.
TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom?
Tempus AI posts its first positive adjusted EBITDA while Butterfly Network pushes revenue gains and efficiency in a rapidly evolving health tech market.
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
Tempus AI: Opportunity To Build Position
Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisition, though organic growth in oncology and data licensing remains robust. The precision medicine company landed another $150 million in data licensing contracts.
TEM Continues to Strengthen Its Genomics Leadership With New Products
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript
Tempus AI, Inc. ( TEM ) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. Welcome back, everyone, to the 2025 Stifel Healthcare Conference.
Tempus AI: Great Buying Opportunity On Recent Weakness
Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid performance in both Genomics and Data/Services segments, with high visibility into future growth. The recent stock pullback, driven by high expectations, presents an attractive entry point for long-term investors willing to accept volatility and premium valuation.
Tempus AI: A Good Bet For The Future Of Health Care
Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testing volumes rising significantly year-over-year. Gross margin expansion, narrowing losses, and a solid cash position highlight TEM's improving profitability and financial health.
